CACNG7

Across TCGA pan-cancer cohorts, CACNG7 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CACNG7 data layer compared with 25 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CACNG7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CACNG7 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

LIHC, UCEC, and READ are the cancer types where CACNG7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.226	0.773	.008	12	view →
UCEC	DFS	Median	All	1.000	0.628	.015	10	view →
READ	OS	Median	All	0.653	0.930	.004	6	view →
STAD	OS	Median	III,IV	1.000	0.359	.023	3	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CACNG7–LIHC (OS)

Open the LIHC breakdown →